Dissemination (Meeting Coverage)

Interim safety and clinical activity data from the Phase 1/2 clinical trial of intravitreal 4D-125 in patients with advanced X-linked retinitis pigmentosa (XLRP) was presented in a late-breaking presentation at the American...

Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) will be highlighted in two presentations during the 2021 Annual Meeting of the American Society of...

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. According to ASRS, its...

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. ASRS 2021 serves to...

A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia (VA), resuscitated cardiac arrest (RCA), and sudden death. The results showed a significantly reduced likelihood for the composite...

The GUIDE-HF trial, presented in a Hot Line Session and simultaneously published in The Lancet, showed benefits of hemodynamic-guided heart failure (HF) management with an implantable device in reducing HF hospitalization [1,2]....

An American trial investigated the potential of valsartan in slowing the course of disease in hypertrophic cardiomyopathy (HCM). The results showed a significantly positive influence on relative cardiac remodeling in the...

The randomized controlled STEP trial revealed that lowering the systolic blood pressure (SBP) to below 130 mmHg in patients over 60 years led to a 26% reduction of adverse cardiovascular (CV) events [1]. A target SBP below 130...

EMPEROR-Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction in the primary composite outcome as well as positive results in secondary outcomes with...

SSaSS trial finds mortality benefit for salt substitute vs salt Reducing the use of discretionary salt and using a salt substitute significantly reduced the risk of stroke and other cardiovascular events in a study of almost...

STEP results demonstrate clinical benefit when systolic drops below 130 mmHg An intensive blood pressure management strategy that lowered systolic blood pressure to less than 130 mmHg significantly reduced the number of strokes,...

Investigators used a Web-based recording system, as well as face-to-face regional benchmark analysis and educational meetings, in the BLITZ-HF prospective study to evaluate and improve adherence to heart failure (HF)...

With data lacking on acute coronary syndrome (ACS) in patients with heart failure (HF), researchers examined the characteristics and outcomes of non-ST elevation ACS (NSTACS) in patients with and without a prior medical history...

With sodium-glucose co-transporter 2 (SGLT-2) inhibitors becoming increasingly relevant for the treatment and prevention of heart failure (HF), study investigators sought to assess various SGLT-2 inhibitors in patients with...

To evaluate the cardiovascular (CV) benefits of sodium-glucose co-transporter 2 (SGLT-2) inhibitors according to 1) patient history of heart failure (HF) and 2) severity of left ventricular ejection fraction (LVEF) reduction in...

To examine outcomes in patients with chronic kidney disease, or CKD, with and without type 2 diabetes by history of HF at baseline, researchers assessed data on 4,304 patients—including 468 with a diagnosis of HF at...

A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...

The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...

The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia. The first results of this study demonstrated that acalabrutinib had...

Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study...